<DOC>
	<DOCNO>NCT01154933</DOCNO>
	<brief_summary>Exenatide show result well glycemic control type II diabetes patient . Obesity diabetes state increase inflammation ; exenatide expect lead decrease inflammation virtue well glycemic control weight loss . The purpose study determine addition Exenatide diabetic patient reduce requirement insulin particularly short act insulin . Exenatide may also lead decreased inflammation virtue well glycemic control weight loss , independent effect .</brief_summary>
	<brief_title>Exeantide Type 2 Diabetes Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Males female 2075 year age inclusive . Type 2 diabetes On insulin therapy HbA1c ≥7.5 % ≤ 9 % BMI ≥ 30 kg/m2 Subjects statins , ACE inhibitor , metformin , thiazolidinediones antioxidant allow long stable dos compound dosage change study . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week Pregnancy Hepatic disease ( abnormal LFT 's ) Use DPP4 inhibitor . Renal impairment ( serum creatinine &gt; 1.5 ) Participation concurrent clinical trial Any lifethreatening , noncardiac disease Uncontrolled hypertension ( BP &gt; 160/100 mm Hg ) Congestive Heart Failure . Use investigational agent therapeutic regimen within 30 day study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>obesity</keyword>
</DOC>